TNF and rheumatoid arthritis: Thus, while we observed that anti-TNFs were the most frequent choice of b/tsDMARD treatment across every BMI category in both cohorts, there was a slight tendency for lower anti-TNF use among RA patients in higher BMI categories, which could indicate that clinical decision-making is in line with these previous findings.